There has been a lot of buzz lately about the use of precision medicine in the treatment of cancer. In a previous blog, we talked about the article in Popular Science that discussed the process of how using genetics to match up the tumor to the drug may be the answer but it is not without its caveat’s.
A new drug that uses a different precision approach may be the answer since its cure rates are so high.
Loxo Oncology, a Connecticut based bio tech company is taking a different approach to the genetic uniqueness of the tumor, instead of trying to target the particular tissue as most of the newest oncology drugs are trying to do. Perhaps they are on to something big, and profitable.
Sometimes, you need to think differently to solve a problem, rather than follow everyone else.
Check out this article that was recently featured in Forbes.
A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here’s What It Teaches Us
Matthew Herper Forbes Staff
Derek Laurie was working as a tow truck driver, living in a suburb outside Rochester, New York, and supporting two small children. It was tough work. He climbed under wrecked vehicles, or swam into ponds. So he thought the pains were pulled muscles. Maybe he was drinking too much beer. He stayed in denial until the tumor was pressing against his spine and he couldn’t walk. When he finally went to an emergency room in Rochester, he was told he had stage IV cancer and a year or two to live.
“They still don’t know where it came from or why it came,” says Laurie, 28. “Nobody knows why it is. They just know it’s an ugly gene in your body that makes you die.”